* Voyager Therapeutics Inc VYGR.OQ VYGR.O is expected
to show
a rise in quarterly revenue when it reports results on May 9.
* The Cambridge Massachusetts-based company is expected to
report
a 9,187.2% increase in revenue to $61.11 million from $658
thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Voyager
Therapeutics Inc
is for earnings of $1.12 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months.
* Wall Street's median 12-month price target for Voyager
Therapeutics Inc is $10, above its last closing price
of $7.83.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.54 -0.55 -0.61 Missed -11.5
Sep. 30 2022 -0.31 -0.32 0.45 Beat 241.9
Jun. 30 2022 -0.48 -0.32 -0.50 Missed -57.5
Mar. 31 2022 -0.25 -0.34 -0.56 Missed -62.7
Dec. -0.71 -0.32 0.15 Beat 147.4
31 2021
Sep. 30 2021 -0.74 -0.73 -0.67 Beat 7.9
Jun. 30 2021 -0.72 -0.71 -0.80 Missed -12.3
Mar. 31 2021 -0.66 -0.66 -0.58 Beat 11.6
This summary was machine generated May 5 at 16:33 GMT. All
figures in US dollars unless otherwise stated